Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Carvedilol Formulations Comparing Carvedilol 12.5 mg Tablets of Ranbaxy Laboratories With Coreg® 12.5 mg Tablets of Glaxosmithkline in Healthy, Adult, Human Subjects Under Fed Conditions

NCT00775619 is registered in ClinicalTrials.gov with Ranbaxy Laboratories Limited as lead sponsor.

NCT NCT00775619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00775619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Carvedilol Formulations Comparing Carvedilol 12.5 mg Tablets of Ranbaxy Laboratories With Coreg® 12.5 mg Tablets of Glaxosmithkline in Healthy, Adult, Human Subjects Under Fed Conditions
Lead sponsor
Ranbaxy Laboratories Limited
Phase
Not applicable
Overall status
Completed
Start date
September 30, 2003
Completion date
December 31, 2003
Enrollment
40 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy